So all present voted. Maybe 2 more in morning session. I think this is huge, seemed more dicey than some would have you believe. My sources said alot of shorters were basing their bets on if not getting approved because of bleeding issues. They use a paid source for this information for shorting alot of bios...looks like they got this one wrong. Shorters may try to influence trading in pre-markets. don't be fooled...hang on to your shares.
Bleeding issue actually turned out to be a non event. Caused in most cases by stomach ulcers, which also applied to the comparator drug studies as well. Bigger issue I think was the elevated liver issue, but the study group was pretty sick with all types of problems from alcoholism, Hept "C" and drug addiction. So just their medications alone could have caused the elevated liver readings. I got concerned when they were looking at the complete resolution statistics between our drug, and the comparator drug. Didn't look so good in the
first Phase III trial but thankfully it showed nicely in the last one. Oh well...Looks like we have a real
winner here folks so hang in there and let's see what happens. A great day for DRTX longs.